Glomerular Filtration Rate and Aging: Another Longitudinal Study--A Long Time Coming! by DELANAYE, Pierre & Glassock, rj
E-Mail karger@karger.com
 Clinical Practice: Editorial 
 Nephron 
 DOI: 10.1159/000439147 
 Glomerular Filtration Rate and Aging: 
Another Longitudinal Study – A Long 
Time Coming! 
 Pierre Delanaye a    Richard J. Glassock b 
 a  Department of Nephrology Dialysis Transplantation, University of Liège,  Liege , Belgium;  b  Geffen School of 
Medicine at UCLA,  Los Angeles, Calif. , USA
 
and that nearly one-third of these subjects had stable or 
even increasing Ccr with aging. However, this study had 
several limitations. The health status of the subjects was 
poorly described and an unknown number had type 2 
diabetes, a disorder known to have a marked influence on 
GFR, even in the absence of proteinuria  [10] . Moreover, 
GFR itself was not measured and 24 h endogenous Ccr is 
no longer recommended to estimate GFR because of lack 
of precision and high intra-individual, between test vari-
ation  [11] . This last point is particularly relevant for lon-
gitudinal studies  [12] , as statistically significant slopes for 
a change of GFR or Ccr require many points of observa-
tion. Too few points were available in many patients in 
the Baltimore Longitudinal Study of Aging.
 The study by Malmgren et al.  [13] in the current issue 
of  Nephron can be considered as partially remedying 
some of the deficiencies of earlier studies. Indeed, the au-
thors followed eGFR, but not mGFR, using several estab-
lished serum creatinine-based estimating equations in a 
large cohort of elderly Swedish women longitudinally for 
10 years. They showed interesting results concerning the 
prevalence of chronic kidney disease (CKD) in the elder-
ly, demonstrated the average decline of eGFR over time 
in the elderly and, lastly, examined the association be-
 The conjecture that measured glomerular filtration 
rate (mGFR) declines with aging, perhaps inevitably, is 
supported by many studies in the early literature on the 
subject  [1–3] . More recent publications have amply con-
firmed that declining mGFR occurs in ‘healthy’ and even 
‘very-healthy’ subjects, such as living related donors for 
kidney transplantation  [4, 5] . In addition, numerous epi-
demiological studies have described such declining GFR 
with aging in samples of apparently healthy populations 
studied with estimated GFR (eGFR) rather than mGFR 
 [6, 7] . The studies with mGFR were limited to a relatively 
small sample size, especially in the elderly, whereas the 
epidemiological studies may have been confounded 
by  inaccuracies in the eGFR equations in elderly sub-
jects. Moreover, all these studies shared the same impor-
tant limitation: they are cross-sectional in character and 
thus impaired by survival biases. Very few longitudinal 
studies are available in the literature  [8] . The ‘Baltimore 
Longitudinal Study of Aging’, published in 1985, was 
seminal and frequently quoted  [9] . Between 1958 and 
1981, this study followed 254 apparently ‘healthy’ males, 
of varying age, with serial endogenous true creatinine 
clearances (Ccr), as an approximation of GFR. They 
found that the mean decline in Ccr was 0.75 ml/min/year, 
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tween decreased eGFR and mortality. These studies have 
particular meaning for the definition of what constitutes 
CKD in an elderly and aging population.
 The Prevalence of CKD or ‘Decreased GFR’ in Aging 
Subjects 
 The threshold for accepting ‘decreased GFR’ for de-
fining the presence of ‘CKD’ in the elderly is difficult to 
determine and is also the subject of heated debate  [14, 
15] . We, and others, have challenged the definition of 
CKD chosen in the 2013 KDIGO (for ‘Kidney Disease 
Improving Global Outcome’) guidelines, which consid-
er CKD to be present in any subject, regardless of chron-
ologic age, when the GFR falls persistently (>3 months) 
below a value of 60 ml/min/1.73 m 2  [16] , even in the 
absence of other signs of kidney injury, such as protein-
uria. We suggest that this non-age calibrated thresh-
old leads to a substantial overestimation of CKD preva-
lence, especially in the elderly  [17] and have proposed 
that CKD Category 3A (an isolated GFR between 45 and 
60 ml/min/1.73 m 2 ) not be regarded as bona fide CKD 
in the elderly; thus, CKD Category 3B (an isolated GFR 
of <45 ml/min/1.73 m 2 ) becomes the ‘new’ threshold for 
CKD definition  [14] . Very importantly, we emphasize 
the fact that this new proposal is only applicable in sub-
jects without any albuminuria or other signs of kidney 
damage. Also, the chronicity must be confirmed by a 
persistent result after 3 months. The choice of GFR 
threshold for defining CKD has an appreciable impact 
on the epidemiology of CKD in the elderly, such as in 
the study reported by Malmgren et al.  [13] in a recent 
issue of  Nephron . This study shows that CKD Category 
3A includes a very large proportion of the population 
and that this proportion increases greatly with aging. 
The absence of measured albuminuria is a limitation of 
the study by Malmgren et al.  [13] , and one cannot be 
certain of the true prevalence of CKD in this population. 
However, the majority of elderly subjects reach CKD di-
agnosis according to the decreased eGFR only, without 
any reference to albuminuria  [16] .
 Another limitation of the study by Malmgren et al.  [13] 
is the absence of mGFR values, as appropriately acknowl-
edged by the authors. In the absence of mGFR values, the 
authors have elected to consider different creatinine-
based equations to estimate GFR and thereby to evaluate 
the prevalence of CKD. Although the KDIGO recom-
mended the CKD-EPI (for ‘Chronic Kidney Disease Epi-
demiology Collaboration’) equation to estimate GFR 
 [16] , the ideal choice of an eGFR equation is not so obvi-
ous in elderly people  [18–20] . As shown by Malmgren et 
al.  [13] , the prevalence of CKD in the elderly population 
is highly dependent on the equation used to evaluate 
eGFR. The data from the study by Malmgren et al.  [13] 
show that in elderly subjects, the prevalence of decreased 
GFR is higher with the Berlin Initiative Study  [18] or the 
Lund–Malmö equations  [19] as compared to the Modifi-
cation of Diet in Renal Disease or the CKD-EPI equations 
 [13, 18] . A definitive answer concerning the superiority 
of one eGFR equation over another is simply not possible 
from this study because mGFR was not available. We can 
just comment on the following facts: on one side, the 
 Berlin Initiative Study equation has been specifically de-
veloped in an elderly population  [18] ; on the other side, 
the Lund-Malmö equation has been developed from a 
 Swedish database  [19] .
 The Slope of GFR with Aging 
 Within 10 years, the women in the study by Malmgren 
et al.  [13] lost 22% of their initial eGFR. The mean 
loss was 16.6 ml/min/1.73 m 2 per decade, which is more 
than twice the rate of decline in Ccr observed in the 
male-dominated Baltimore study, as cited previously. 
Also, results differ between the present study and the 
 Baltimore  study regarding the proportion of subjects 
with stable or improving eGFR (a very low proportion 
of such subjects was observed in the Swedish study). 
However, direct comparison is difficult because age, 
health status, method of GFR assessment and length of 
follow-up were not similar between the 2 studies. Also, 
an important difference between the 2 studies could be 
explained by the way the analyses have been performed. 
Indeed, slope (of eGFR or Ccr over time) has been mea-
sured only in 314 women who survived for the 10-year 
period in the Swedish study, though the slope has been 
calculated in all patients in the Baltimore cohort with 
different follow-up periods  [9, 13] . This analysis ‘only in 
the survivors’ is very important to keep in mind when 
interpreting the results of the study. Death is an impor-
tant competing risk in this elderly population  [21] . Two 
characteristics of the eGFR slopes, as described by 
Malmgren et al.  [13] , must be interpreted in the light of 
this competing risk: (i) the non-linearity of eGFR slope 
with time; in other words, the accelerated loss of eGFR 
between 75 and 85 years compared to the 70–75 years 
period and (ii) the difference in eGFR slopes observed 
according to baseline eGFR, the decrease being more 
 exaggerated in patients with high initial eGFR values. 
Indeed, it could be suggested that patients with low base-
line GFR and rapid decrease in GFR will die before 
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even if the slope description is of interest, it remains only 
applicable in this age range.
 The Definition of CKD and Mortality Risk 
 The association between decreased eGFR (i.e. <60 ml/
min/1.73 m 2 ) and mortality (global or cardiovascular) has 
been used as an important justification for the choice of 
the unique GFR threshold for CKD definition in the 
 KDIGO guidelines  [16] . However, such a unique ‘prog-
nosis-based’ threshold for CKD definition is questionable 
for several reasons  [15] : (i) this leads to a large gap be-
tween eGFR sensed to be the breakpoint to predict mor-
tality (or other events), that is, 60 ml/min/1.73 m 2  [22] 
and eGFR actually observed in healthy populations  [6, 7] . 
For example, in the healthy population described by van 
den Brand et al. [6] , low normal eGFR value (defined as 
the percentile 5) is 94 and 85 ml/min/1.73 m 2 at 25–29 
years, 67 and 70 ml/min/1.73 m 2 at 50–54 years and 44 
and 51 ml/min/1.73 m 2 at 70–74 years for men and wom-
en, respectively. This gap between prognosis and ‘real-
life’ results can only be decreased by using an age-cali-
brated definition of CKD  [14, 23] . (ii) The prognosis-
based threshold could be different according to the ‘event’ 
considered and/or the methodology used. For example, 
the first article suggesting that increased all-cause mortal-
ity risk was independently associated with decreased 
eGFR was published in 2004 by Go et al.  [24] . The authors 
showed that patients with eGFR of 45–59 ml/min/1.73 m 2 
have a higher risk of all-cause mortality compared to an 
eGFR of  ≥ 60 ml/min/1.73 m 2 . However, this increased 
risk disappeared completely when a subgroup of subjects 
with repeated measurement of eGFR was considered 
whereas the increased risk for cardiovascular death re-
mained significant at 45–59 ml/min/1.73 m 2 in the same 
subset of subjects with repeated eGFR measures. (iii) Sur-
prisingly, the ‘prognosis’ approach could lead to different 
CKD definitions if other GFR biomarkers, like cystatin C 
were considered. Indeed, the threshold for CKD diagno-
sis should move from 60 to 80 ml/min/1.73 m 2 , as cystatin 
C-based equation results below this threshold were asso-
ciated with worse prognosis (and this association was 
stronger than with creatinine-based equation)  [25] . (iv) 
Age, by nature the most important variable for mortality 
prediction, is also an important variable in all estimating 
equations and could thus subsume all these associations.
 Having underlined the limitations of such a ‘progno-
sis-based’ CKD definition, we cannot ignore the fact, 
once again, that this is the fundamental argument of the 
KDIGO guidelines. Moreover, this point should be dis-
cussed because the association of eGFR with mortality 
risk is certainly another interesting part of the study pub-
lished by Malmgren et al.  [13] . The authors found that the 
risk of mortality is significantly higher in the elderly pop-
ulation categorized as CKD 3B (or higher) than for Cat-
egory CKD 3A. At first sight, the lack of significant asso-
ciation between Category 3A and mortality in elderly in 
the study by Malmgren et al.  [13] could be considered 
contradictory with prior publications supporting the 
KDIGO guidelines for CKD definition. Indeed, in the 
first CKD-EPI consortium study  [22] , the reference value 
of eGFR used for the calculation of hazards ratio (HR) 
was 95 ml/min/1.73 m 2 . Later in 2012, the same consor-
tium, with Hallan as first author, focused on the variable 
of age  [26] . In this analysis the risk of mortality was also 
found to be increased when eGFR was <60 ml/min/ 
1.73 m 2 in all categories of age, when the reference value 
of eGFR for HR calculations was 80 ml/min/1.73 m 2 , and 
not 95 ml/min/1.73 m 2 . The authors thus implicitly ac-
cept as fact that the ‘normal’ GFR changes with aging. 
Moreover, Hallan’s paper is subject to different interpre-
tations based on how one selects the value of the eGFR for 
reference group for HR calculations. The Hallan analysis 
is compatible with an age-dependent effect on the thresh-
old of eGFR for identifying an increasing risk (HR) for 
all-cause mortality, and it can be deduced that in patients 
>65 years, there is no significant higher risk of mortality 
associated with CKD Category 3A, the risk being signifi-
cant only in CKD Category 3B. Other cross-sectional data 
from a large Canadian study also confirmed that life ex-
pectancy was similar in the elderly if CKD Category 3A 
or CKD Category 1–2 were considered  [27] . The results 
found by the longitudinal study of Malmgren et al.  [13] 
parallel these findings from cross-sectional analyses and 
support an argument for an age-calibrated eGFR for the 
definition of CKD even within the limitations of a ‘prog-
nosis-based’ CKD definition.
 In conclusion, the study by Malmgren et al.  [13] is a 
welcome addition to the growing literature describing the 
evolution of renal function with aging. Taken as a whole, 
it supports the notion that a single, non-age stratified 
threshold value for eGFR to define CKD is not appropri-
ate. The extent to which such absolute thresholds overes-
timate the prevalence of CKD in the elderly remains a 
valid topic for debate.
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